List of Excipients in Branded Drug TESTOSTERONE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Par Pharmaceutical Inc	TESTOSTERONE	testosterone	0603-7831	ALCOHOL
Par Pharmaceutical Inc	TESTOSTERONE	testosterone	0603-7831	BUTYLATED HYDROXYTOLUENE
Par Pharmaceutical Inc	TESTOSTERONE	testosterone	0603-7831	ISOPROPYL ALCOHOL
Par Pharmaceutical Inc	TESTOSTERONE	testosterone	0603-7831	OLEIC ACID
Par Pharmaceutical Inc	TESTOSTERONE	testosterone	0603-7831	PROPYLENE GLYCOL

Generic Drugs Containing TESTOSTERONE

Company	Ingredient	NDC	Excipient
Actavis Pharma Inc	testosterone	0591-2114	ALCOHOL
Actavis Pharma Inc	testosterone	0591-2114	ISOPROPYL ALCOHOL
Actavis Pharma Inc	testosterone	0591-2114	OCTISALATE
Actavis Pharma Inc	testosterone	0591-2114	POVIDONE K90
Actavis Pharma Inc	testosterone	0591-2363	ALCOHOL

What are the Most Frequently-Used Excipients in TESTOSTERONE?

# Of NDCs	Excipient
34	ALCOHOL
1	BUTYLATED HYDROXYTOLUENE
1	CARBOMER 1342
1	CARBOMER 940
2	CARBOMER 980

Testosterone Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Testosterone is a mature active pharmaceutical ingredient with broad generic availability but continuing commercial opportunity in differentiated delivery systems. The strongest opportunities are in transdermal absorption, long-acting injectable tolerability, oral lipid-based delivery, nasal administration, implant systems, and excipient-driven improvements in safety, adherence, storage, and administration.

Excipient selection is commercially important because testosterone has low aqueous solubility, high lipophilicity, extensive first-pass metabolism when administered orally, and dose-dependent transfer and absorption risks in topical products. Formulation patents and device combinations often provide stronger lifecycle protection than the testosterone molecule itself.

What excipient strategies are most valuable for testosterone products?

The highest-value strategy is to match the excipient system to the route-specific failure mode.

Route	Primary formulation problem	Relevant excipient strategy	Commercial objective
Transdermal gel	Variable absorption, skin irritation, transfer to contacts	Volatile solvents, penetration enhancers, gelling agents, humectants, film-forming polymers	Improve exposure consistency and reduce transfer
Transdermal patch	Skin adhesion and irritation	Pressure-sensitive adhesives, permeation enhancers, backing layers, release liners	Extend wear time and improve tolerability
Intramuscular injection	Pain, viscosity, crystallization, depot release	Vegetable oils, co-solvents, benzyl alcohol, benzyl benzoate, viscosity modifiers	Reduce injection burden and extend dosing intervals
Subcutaneous autoinjector	High viscosity, injection force, dose delivery	Oil systems, viscosity control, lubricants, device-compatible excipients	Enable self-administration
Oral softgel	Low bioavailability and food dependence	Lipid vehicles, surfactants, co-solvents, self-emulsifying systems	Improve absorption and reduce dosing variability
Nasal gel	Mucosal clearance and local irritation	Mucoadhesive polymers, humectants, pH buffers, preservatives	Increase residence time and dosing reliability
Implant	Controlled release and surgical handling	Biocompatible polymers, coatings, radiopaque materials	Extend treatment duration and reduce patient adherence demands

The best commercial products do not compete only on testosterone dose. They compete on total treatment burden, pharmacokinetic stability, administration setting, transfer risk, food effect, injection frequency, and patient persistence.

Which testosterone excipients are used in marketed products?

Commercial testosterone products use route-specific excipient platforms rather than a single standard formulation.

Transdermal gels

Marketed testosterone gels commonly use alcohol-based solvent systems with penetration-enhancing excipients and carbomer-type polymers. Representative products include AndroGel and generic testosterone gel products.

Typical excipient functions include:

• Ethanol or other volatile solvents to dissolve testosterone and promote rapid drying.
• Isopropyl myristate or related lipophilic penetration enhancers.
• Carbomers or other polymers to create a gel structure.
• Water and humectants to control skin feel and evaporation.
• Neutralizing agents to adjust viscosity and pH.
• Film-forming or rheology-modifying materials to control residue and transfer.

The commercial weaknesses of gel formulations are well established. Absorption varies among patients, application must be repeated daily, and unintentional transfer can expose partners or children. Excipient improvements that reduce residue, accelerate drying, lower transfer after application, or maintain exposure across different skin types have direct commercial value.

A differentiated gel may support claims directed to composition, application site, drying behavior, transfer reduction, dosing consistency, or pharmacokinetic performance.

Transdermal patches

Testosterone patches use adhesive matrices or reservoirs combined with permeation-enhancing excipients. Androderm was a prominent testosterone patch product in the United States, although it was discontinued.

Patch development is constrained by:

• Skin irritation from adhesives and penetration enhancers.
• Loss of adhesion during sweating or bathing.
• Limited drug loading.
• Variability in skin permeability.
• Manufacturing complexity for multilayer systems.

Commercial opportunity remains in low-irritation adhesives, longer-wear patches, smaller patch footprints, and systems that reduce testosterone crystallization within the adhesive matrix.

Long-acting intramuscular injections

Testosterone undecanoate products such as Aveed use an oil-based depot system. Conventional testosterone cypionate and testosterone enanthate injections also rely on oil vehicles.

Common excipient classes include:

• Refined vegetable oils as the depot vehicle.
• Benzyl benzoate as a co-solvent and solubilizer.
• Benzyl alcohol as a preservative in multidose products.
• Nitrogen or other headspace controls for oxidation management.
• Container and closure materials selected for compatibility with oily formulations.

The main product-development opportunities are lower injection volume, reduced injection pain, lower viscosity, more predictable release, and improved storage stability. A long-acting formulation that moves administration from a clinic to a supervised or self-administered setting may also create commercial differentiation, subject to FDA device and administration requirements.

Oil selection is a critical development variable. Chain length, oxidation profile, water content, peroxide formation, and interaction with elastomeric closures can affect stability and impurities. The excipient must also support reproducible depot formation after injection.

How does oral testosterone excipient technology create commercial opportunities?

Oral testosterone products have the largest excipient-driven differentiation potential because oral administration must overcome extensive hepatic metabolism.

Jatenzo, Tlando, and Kyzatrex use oral testosterone undecanoate approaches designed to improve systemic exposure through lipid-associated absorption. These products are distinct from traditional oral testosterone formulations that could produce clinically unacceptable hepatic effects or inadequate exposure.

Lipid-based delivery

Useful formulation components include:

• Medium- and long-chain triglycerides.
• Fatty acids and fatty acid esters.
• Surfactants.
• Cosolvents.
• Lipophilic absorption promoters.
• Self-emulsifying or self-microemulsifying systems.

The formulation objective is to maintain testosterone undecanoate in a solubilized state, promote intestinal lymphatic transport, and reduce dependence on conventional hepatic first-pass metabolism.

Commercially relevant performance claims include:

• Reduced variability between fed and fasted administration.
• Lower food-effect magnitude.
• Fewer daily doses.
• More predictable serum testosterone.
• Lower gastrointestinal burden.
• Improved capsule size and swallowability.

Food dependence is a major competitive issue. A formulation that requires administration with a high-fat meal creates adherence friction and may limit use in patients with dietary restrictions. Excipient systems that preserve exposure with a standard meal or under less restrictive conditions could support premium positioning.

Softgel manufacturing

Oral testosterone undecanoate softgels require control of fill uniformity, capsule-shell compatibility, leakage, oxygen exposure, and long-term stability. Key manufacturing risks include:

• Testosterone undecanoate precipitation.
• Shell brittleness or migration of fill components.
• Oxidation of unsaturated oils.
• Fill-weight variation.
• Incompatibility with sealing materials.
• Dissolution changes after storage.

A formulation platform with scalable encapsulation, lower fill volume, and stable dissolution can produce licensing value even where composition-of-matter protection is unavailable.

What excipient opportunities exist in nasal testosterone products?

Natesto uses intranasal testosterone delivery. Nasal systems can avoid gastrointestinal absorption and provide a route that is less visible than a gel and less invasive than an injection.

Nasal excipient strategies include:

• Mucoadhesive polymers to increase residence time.
• Humectants to limit mucosal drying.
• Buffers to maintain a tolerable pH.
• Osmolality modifiers.
• Surfactants or cosolvents to support testosterone solubilization.
• Preservative systems compatible with repeated nasal dosing.

The central formulation tradeoff is residence time versus mucosal tolerability. Stronger mucoadhesion may improve absorption but increase local irritation, altered mucus clearance, or patient discomfort. Product differentiation may focus on smaller dose volume, lower dosing frequency, improved spray reproducibility, and reduced nasal adverse events.

Nasal testosterone products face a narrower patient-use window than oral or injectable products. Their commercial position is strongest among patients who reject injections and cannot reliably use topical gels.

How can excipients improve subcutaneous testosterone delivery?

Subcutaneous testosterone products, including autoinjector-based systems such as Xyosted, create a commercial pathway between daily topical treatment and clinic-administered intramuscular therapy.

The formulation and device must jointly manage:

• Viscosity.
• Injection force.
• Needle gauge.
• Dose volume.
• Syringe and elastomer compatibility.
• Delivery time.
• Local tissue tolerability.
• Stability during storage and shipment.

For subcutaneous delivery, excipient selection cannot be separated from device design. An oil formulation that is chemically stable may still be unsuitable if it produces excessive injection force or incomplete delivery. Device-compatible formulations can support combination-product patents covering the formulation, container, needle, autoinjector, and administration method.

The strongest commercial proposition is predictable exposure with less frequent home administration. The main constraints are local injection-site reactions, patient training, controlled-substance handling, and payer acceptance.

What formulation patents protect testosterone products?

Testosterone molecule patents have limited relevance because testosterone and several testosterone esters are long-established compounds. Commercial protection usually comes from formulation, delivery, manufacturing, device, and method-of-use claims.

Common patent claim categories

Claim category	Protected subject matter	Typical commercial purpose
Composition	Excipient ratios, solvent systems, lipid vehicles, polymer matrices	Block substitute formulations
Dosage form	Gel, softgel, depot injection, implant, spray, patch	Protect the marketed presentation
Pharmacokinetics	Exposure profile, peak-to-trough control, food-effect reduction	Link formulation to clinical performance
Manufacturing	Mixing, sterilization, filling, encapsulation, crystallization control	Create manufacturing barriers
Device combination	Autoinjector, metering pump, nasal actuator, implant inserter	Protect administration system
Method of use	Hypogonadism treatment, dose titration, administration schedule	Extend market exclusivity
Safety or handling	Reduced transfer, lower injection pain, controlled release	Support differentiation and labeling

Excipient claims are strongest when they define a narrow, reproducible relationship between excipient composition and a clinically meaningful result. Broad claims to commonly used ethanol, oil, carbomer, or benzyl alcohol systems are more vulnerable to invalidity and design-around challenges.

The U.S. patent term generally runs 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment and possible patent-term extension. FDA-listed patents for approved products are evaluated through the Orange Book, while formulation and process patents that are not eligible for listing may remain relevant in litigation or licensing negotiations.[1][2]

When does testosterone lose exclusivity and what is the generic entry risk?

Testosterone has already lost molecule-level exclusivity in the United States. Generic entry risk therefore depends on the product presentation.

Product category	Generic or competitive status	Primary remaining barrier
Testosterone gel	Multiple generic products available	Formulation similarity, ANDA approval, label carve-outs
Testosterone cypionate injection	Long-established generic market	Manufacturing capacity and supply reliability
Testosterone enanthate injection	Generic and branded competition	Depot performance and container compatibility
Testosterone undecanoate injection	More limited competition than conventional esters	Complex depot formulation, clinical and manufacturing requirements
Oral testosterone undecanoate	Branded differentiated products	Lipid formulation, food-effect data, patents, regulatory exclusivity
Nasal testosterone	Limited direct competition	Device, local tolerability, formulation and clinical requirements
Subcutaneous autoinjector	Limited direct competition	Combination-product development and device patents
Implant pellets	Established product category	Sterility, pellet manufacture, insertion procedure

ANDA applicants may challenge listed Orange Book patents through Paragraph IV certifications. The reference sponsor can trigger a 30-month stay by filing patent litigation within the statutory period, subject to the Hatch-Waxman framework.[3] The risk is highest for oral, nasal, and autoinjector products where formulation and device patents may be central to the product's commercial identity.

For generic gel and conventional injectable products, the key risks are usually pricing, supply-chain scale, manufacturing validation, and substitution rather than molecule patents.

What is the FDA regulatory status of testosterone formulations?

Testosterone products are FDA-approved prescription therapies for specific forms of hypogonadism associated with a medical condition. Testosterone is also a controlled substance in the United States, classified as Schedule III under the Controlled Substances Act.[4]

Relevant FDA pathways include:

• 505(b)(1) NDA approval for a new testosterone formulation.
• 505(b)(2) NDA approval where the sponsor relies partly on existing safety or efficacy information.
• ANDA approval for therapeutically equivalent generic products.
• Combination-product review when a drug is supplied with an autoinjector, pump, applicator, or other delivery device.

Excipient changes can trigger a new drug application supplement, additional stability work, comparative pharmacokinetic testing, local tolerability studies, or new clinical trials. The regulatory value of an excipient depends on whether it changes exposure, absorption site, safety, administration frequency, or product performance.

The FDA Inactive Ingredient Database is a useful starting point for prior-use analysis, but prior use in one route or dosage form does not establish automatic suitability in another.[5]

How should a testosterone excipient platform be evaluated for patent strength?

A strong excipient platform should satisfy five conditions:

1. The formulation produces a measurable clinical or pharmaceutical benefit.
2. The benefit depends on a defined excipient combination rather than a routine substitution.
3. The composition is difficult to reverse-engineer or design around.
4. The product can be manufactured at commercial scale.
5. The formulation supports a regulatory label or measurable pharmacokinetic advantage.

Patent strength is higher when the claims include narrow excipient ranges, defined particle or droplet characteristics, release profiles, viscosity limits, impurity thresholds, or demonstrated exposure advantages.

Patent strength is lower when claims cover familiar excipients at conventional concentrations without a reliable unexpected result. Common excipient substitutions are often vulnerable to obviousness challenges, especially where the formulation objective is predictable.

Freedom-to-operate analysis should cover:

• U.S. and foreign composition patents.
• Device and combination-product patents.
• Method-of-use patents.
• Manufacturing and sterilization patents.
• Third-party excipient licenses.
• Supplier ownership of proprietary lipid or polymer systems.
• Patent-term adjustment and terminal disclaimers.
• Orange Book-listed patents and non-listed patent assertions.

Which commercial opportunities are most attractive?

High-potential opportunities

• Oral testosterone undecanoate with reduced food dependence.
• Lower-volume or lower-viscosity subcutaneous formulations.
• Long-acting injectable systems with reduced injection pain.
• Low-transfer transdermal gels with improved drying and skin tolerability.
• Nasal systems with longer residence time and lower local irritation.
• Implant formulations with predictable release and less frequent replacement.
• Excipient platforms that improve stability without introducing new toxicological concerns.
• Generic products with reliable supply, smaller packaging, and differentiated administration accessories.

Lower-potential opportunities

• Undifferentiated testosterone cypionate or enanthate injections.
• Conventional ethanol-carbomer gels without a measurable transfer or absorption advantage.
• Minor excipient substitutions that do not alter labeling or clinical performance.
• Products dependent on a single specialized excipient supplier without a second-source strategy.

How does testosterone compare with biologic hormone products for excipient commercialization?

Testosterone is a small-molecule steroid, not a biologic. Biosimilar risk does not apply. Competition occurs through ANDAs, 505(b)(2) applications, new NDAs, authorized generics, formulation licenses, and device combinations.

This reduces the burden associated with biologic comparability, but it increases direct formulation competition. A testosterone product can face rapid price erosion after approval if its formulation and delivery system do not create meaningful differentiation.

The commercial advantage is a shorter development path than for many biologics. The disadvantage is that the active ingredient is widely available and manufacturing know-how is mature.

What licensing deals are most valuable in testosterone formulation development?

Licensing value is concentrated in proprietary delivery technology rather than commodity testosterone supply.

Attractive licensable assets include:

• Lipid-based oral absorption systems.
• Mucoadhesive nasal platforms.
• Low-force oil-based injection systems.
• Long-acting biodegradable implant matrices.
• Low-transfer transdermal polymers.
• Autoinjector technologies compatible with viscous or oily formulations.
• Stability-enhancing excipient combinations with regulatory precedent.

A transaction should distinguish ownership of the drug formulation from ownership of the excipient technology, manufacturing process, device, and clinical data package. Royalty economics are stronger when the excipient system is essential to the approved product and difficult to replace without new clinical or regulatory work.

Key Takeaways

• Testosterone molecule exclusivity has expired; commercial protection now depends on formulation, route, device, manufacturing, and method-of-use claims.
• Oral testosterone undecanoate has the greatest excipient-driven opportunity because absorption and food effects determine product performance.
• Subcutaneous autoinjector products require integrated drug-device development, with viscosity and injection force as central constraints.
• Transdermal products can differentiate through reduced transfer, faster drying, lower irritation, and more consistent absorption.
• Nasal products need a balance between mucoadhesion and local tolerability.
• Conventional injectable testosterone is a mature, price-sensitive market with limited room for undifferentiated excipient innovation.
• Testosterone does not face biosimilar competition, but it does face generic, 505(b)(2), authorized-generic, and device-based competition.
• The strongest patents claim defined excipient combinations linked to measurable pharmacokinetic, stability, safety, or administration benefits.
• FDA Inactive Ingredient Database precedent supports development planning but does not eliminate route-specific safety and regulatory requirements.
• Licensing targets should focus on proprietary delivery platforms, device compatibility, and manufacturing advantages.

FAQs

Can a new testosterone excipient formulation receive FDA exclusivity?

Yes. A new formulation may qualify for regulatory exclusivity if it meets the applicable NDA requirements. Patent protection and FDA exclusivity are separate rights and must be analyzed independently.

Are testosterone gel excipients patentable?

Yes, but protection generally depends on a specific composition, concentration range, performance result, manufacturing method, or dosage form. Claims to routine use of common excipients are more vulnerable to validity challenges.

Does testosterone have biosimilar competition?

No. Testosterone is a small-molecule steroid. Market competition uses generic, 505(b)(2), NDA, and device-combination pathways rather than the biosimilar pathway.

Which excipient is best for oral testosterone undecanoate?

Lipid vehicles and self-emulsifying systems are the most commercially relevant categories because they can improve solubilization and lymphatic absorption. The optimal system depends on food effect, dose loading, stability, capsule compatibility, and clinical exposure.

Can an excipient change extend the life of a testosterone product?

An excipient change can support new patent claims, a new dosage form, or regulatory exclusivity only when it creates a qualifying product distinction. A routine manufacturing or formulation change does not automatically extend market protection.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

2. United States Patent and Trademark Office. (2024). Patent term calculator. https://www.uspto.gov/patents/laws/patent-term-calculator

3. U.S. Food and Drug Administration. (2024). ANDA submissions: Refuse-to-receive standards and patent certifications. https://www.fda.gov/drugs/guidance-compliance-regulatory-information

4. U.S. Drug Enforcement Administration. (2024). Controlled substance schedules. https://www.dea.gov/drug-information/drug-scheduling

5. U.S. Food and Drug Administration. (2024). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

6. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/